This white paper summarizes a recent webinar convened by PRECISIONheor, moderated by Dr. Jeroen Jansen, Chief Scientist. The webinar featured a discussion surrounding the use of R for model-based cost-effectiveness analysis, and what can be done to increase its uptake and acceptance.
Following up from her last Insights90, Jacki Chou returns to explain 3 major changes in ICER’s recently released protocol for the 2022 national unsupported price increase assessment.
This month, PRECISIONheor highlights Director, Health Economics, Andrea Berardi.
Modern technology allows for the mass collection of digital health data. Artificial intelligence has become a vital tool for making sense of the huge volume of health data being collected daily through the use of big data analytics (BDA).
Last month, the FDA Office of Prescription Drug Promotion announced they will be conducting a discrete choice experiment study to understand how both patients and physicians weigh attributes of potential treatments.
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
As the US healthcare system has shifted in recent years from a “volume-to-value” framework, there is increasing pressure on the industry to demonstrate the value of innovative therapies early in development, particularly those for diseases that present a large societal burden or for which there remains significant unmet need. The urgency to innovate underscores the importance of strategic partnering: cross-industry collaborations to support evidence generation that will, in turn, advance medical care and health outcomes.
Have you heard about ICER’s new research protocol for assessing price increases of prescription drugs in California? PRECISIONheor’s Jacki Chou kicks off our new Insights90 series by breaking down this new protocol.
This month, PRECISIONheor highlights Vice President Patrick Sullivan, PhD.
This month PRECISIONheor highlights the newest addition to the team, Senior Research Scientist, Rozanne Wilson, PhD.